2-hydroxy-7-methoxy-2-methyl-3-oxo-4H-1,4-benzoxazine-5-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 2-hydroxy-7-methoxy-2-methyl-3-oxo-4H-1,4-benzoxazine-5-carboxylic acid
• 化学式: C₁₁H₁₁NO₆
• 分子量: 253.21
• InChiKey: JBOMNNNMDQWHAY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  105
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Novel small molecule inhibitors of biofilm formation and the novel use of previously identified compounds for inhibition of biofilm formation and applications for drug therapy and medical device coating
  申请人：LININGTON Roger

  公开号：US20160000079A1

  公开（公告）日：2016-01-07

  Novel compounds and the novel use a class of previously identified small molecules for the inhibition of biofilm formation. Inhibition of biofilm formation can play a very important role in contributing to pathogenicity. Bacteria in the biofilm state have been shown to be 10-10,000-fold less susceptible to antibiotic treatment. Estimations made by the Centers for Disease Control (CDC) and the National Institutes of Health (NIH) attribute 65% to 80% of human infections as biofilm mediated. Consequently, biofilm formation is often responsible for chronic infections due to bacterial persistence despite antibiotic treatment.
• US9596855B2
  申请人：——

  公开号：US9596855B2

  公开（公告）日：2017-03-21
• [EN] NOVEL SMALL MOLECULE INHIBITORS OF BIOFILM FORMATION AND THE NOVEL USE OF PREVIOUSLY IDENTIFIED COMPOUNDS FOR INHIBITION OF BIOFILM FORMATION AND APPLICATIONS FOR DRUG THERAPY AND MEDICAL DEVICE COATING<br/>[FR] NOUVEAUX INHIBITEURS À PETITES MOLÉCULES DE LA FORMATION DE BIOFILMS ET NOUVELLE UTILISATION DES COMPOSÉS PRÉCÉDEMMENT IDENTIFIÉS POUR INHIBER LA FORMATION DE BIOFILMS ET APPLICATIONS DE THÉRAPIE MÉDICAMENTEUSE ET DE REVÊTEMENT DE DISPOSITIFS MÉDICAUX
  申请人：LININGTON ROGER

  公开号：WO2014130587A1

  公开（公告）日：2014-08-28

  Novel compounds and the novel use a class of previously identified small molecules for the inhibition of biofilm formation. Inhibition of biofilm formation can play a very important role in contributing to pathogenicity. Bacteria in the biofilm state have been shown to be 10-10,000-fold less susceptible to antibiotic treatment. Estimations made by the Centers for Disease Control (CDC) and the National Institutes of Health (NIH) attribute 65% to 80% of human infections as biofilm mediated. Consequently, biofilm formation is often responsible for chronic infections due to bacterial persistence despite antibiotic treatment.